University of Texas MD Anderson Cancer Center

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th

Generative artificial intelligence firm Generate Biomedicines unveiled a novel protein discovery and development collaboration with Novartis AG on 24 September that it called part of an effort to

ArriVent Biopharma, Inc. executed one of the first initial public offerings by a biopharmaceutical company in the US this year, primarily to fund its lead drug candidate firmonertinib, an EGFR tyrosi